



IBA showcases the latest technology breakthroughs in proton therapy at the ESTRO Conference 2019



Louvain-la-Neuve, Milan, Italy, April 26, 2019 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, will showcase its technology leadership in proton therapy at the 38th Annual European Society for Radiotherapy & Oncology (ESTRO) Meeting and Exhibition being held in Milan from 26-29 April 2019.

Proton therapy is considered one of the most advanced forms of radiation therapy. When investing in a technology that will last for over 30 years, the selection of the right partner is a crucial step in the buying process. Not only is it key to secure the performance of the system, it is also essential to secure the future technology evolution to maximize the return on the investment made in proton therapy.

During the 38th ESTRO, IBA will display the most advanced technologies coming to proton therapy with a focus on motion management, Proton Arc Therapy, and Proton Flash Therapy. These topics will be presented at booth #3500 as well as at the IBA Proton Therapy Conference.

IBA will also present live demonstrations of myQA[®] iON patient QA enabling automated dosimetry QA for data-driven proton therapy. This online log based quality assurance solution will significantly reduce the time to perform Patient QA.



IBA Proton Therapy Conference

On Saturday, April 27th, 2019, IBA is hosting a symposium in Milan with presentations from industry experts in proton therapy:

- Dr. Peyman Kabolizadeh, MD, PhD, Medical Director at Beaumont Health Proton Therapy in Royal Oak Michigan, USA, will present the latest update on Proton Arc Therapy.
- The 1st year experience with the model-based approach for patient selection will be presented by Professor Hans Langendijk from the University Medical Center in Groningen, The Netherlands.
- Dr. Costas Koumenis, Professor of Radiation Oncology Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, will describe the set-up and preliminary data from Proton Flash radiotherapy.

Registration to the IBA proton therapy event is available [here](#).

Latest news from proton therapy practitioners – Meet the Experts on the IBA Booth

Securing the future in proton therapy

Beaumont Health Proton Therapy Center in Royal Oak, Michigan is a leading research center conducting advanced research in particle physics and radiation therapy. As part of its long-lasting joint R&D program with IBA, Beaumont staff have been pioneers in the development of **Proton Arc Therapy**. Beaumont will share its first results using Proton Arc Therapy.

Peyman Kabolizadeh, MD, Ph.D., Medical Director at Beaumont Health Proton Therapy Center will share the latest updates on Proton Arc Therapy on Saturday, April 27th, at 3:45 PM and on Sunday, April 28th at IBA's booth, #3500.

Motion management is another key topic in proton therapy as clinical indications continue to widen at many centers.

Marco Schwarz, MD, PhD, Head of medical physics, Proton Therapy Department Protonterapia Trento will share how to use surface imaging to monitor intrafraction target motion on Saturday, April 27th, at 10:00 AM at IBA's booth, #3500.

Sofie Gillis, Clinical Solution Director at IBA Proton Therapy, will describe treatment techniques for moving targets. A comprehensive approach to treatment of moving targets on Sunday, April 28th at 10:00 am at our IBA booth #3500.

In March 2019 IBA announced the first **Flash irradiation** in an IBA gantry treatment room at the University Medical Centre Groningen (UMCG) in The Netherlands. This novel technique has the



potential to dramatically change the landscape of radiotherapy and patient cancer care by enhancing the therapeutic window with a fast and powerful treatment that delivers a high dose of radiation at an ultra-high dose rate. Flash irradiation also opens the door to a shift in the economics of proton therapy using hypofractionation.

Nicolas Denef, Product Management Director at IBA Proton Therapy, will make two presentations on: “Flash Therapy – A new paradigm of radiotherapy” on Saturday, April 27th and on Monday, April 29th at 1:00 PM on IBA booth #3500.

Securing the performance in Proton Therapy

After a fast installation of the Proteus[®]PLUS* solution by IBA, the University Medical Center Groningen (UMCG) has implemented advanced **selection procedures for proton therapy** in head and neck cancer patients. Preliminary results from its efforts are promising in validating the model-based approach for selecting the patients where proton therapy is the most appropriate treatment and potentially extending this approach to other indications such as breast cancer.

Anne Crijns, MD, PhD, Radiation Oncologist at UMCG, will share her experience of UMCG’s model-based approach & Breast cancer program at our IBA booth #3500 on Monday, April 29th at 10:00 AM.

IBA Dosimetry developed myQA iON which enables automated dosimetry QA for data-driven Proton Therapy. myQA iON is the proprietary **Patient QA software** solution increasing the efficiency, accuracy, and safety of recurrent QA checks in proton therapy. It performs a sophisticated Monte Carlo dose map computation automatically in the background which saves time through task-based workflow, automation, and log file QA.

Simon Marcelis, Business line Director Particle Therapy at IBA Dosimetry, will demonstrate “How can you automatize your Daily QA” on Sunday, April 28th at 1:00 PM on IBA booth #3500.

Securing the investment in proton therapy

Following a record nine-month installation program by IBA, Proton Partners International has been treating patients with the Proteus[®]ONE* solution at Rutherford Cancer Centre in Newport, South Wales for a year.

John Pettingell, Chief Physicist & Head of Radiotherapy at the Rutherford Cancer Centre, will describe the Centre’s first-year experience with proton therapy and the transition to proton therapy in the UK on Monday, April 29th, at 3:45 PM at our IBA’s booth, #3500.



Partnering with key market leaders in radiation oncology for optimal healthcare solutions

Thanks to its long-lasting partnerships with Elekta, Philips Healthcare, and RaySearch, IBA is able to showcase multiple workflow solutions designed to integrate proton therapy in the clinic and further illustrate its open integration approach.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. IBA is the worldwide technology leader in the field of Proton Therapy, considered to be the most advanced form of radiation therapy available today. IBA's Proton Therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale Proton Therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry division which develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing approximately 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

**Proteus®ONE and Proteus®PLUS are brand names of Proteus 235*

For further information, please contact:

IBA

Aymeric Harmant

Global Marketing Director

+32 10 203 796

global.marketing@iba-group.com